Skip to main content
OpenTrials
Completed

NCT Number: NCT07746193

Prevalence of Suicidal Risk in Psychiatric Settings

France is among the countries with one of the highest suicide rates in the world, far ahead of its neighboring nations [Wasserman et al., 2012]. Suicide represents the second leading cause of death among 15-24-year-olds, just after road accidents, and the leading cause of death among 25-34-year-olds. In this context, a better utilization of all components of the healthcare system seems highly desirable, particularly through greater involvement of community psychiatrists in suicide prevention strategies. Approximately 25% of individuals who die by suicide have consulted a psychiatrist in the month preceding their death [Luoma et al., 2002], yet few data are available on this topic, especially regarding consultations with community psychiatrists outside of hospital settings.

Study objectives Main objective To assess the prevalence of suicidal risk during the 15 days preceding an outpatient psychiatric consultation in the Clermont-Ferrand area.

Main secondary objectives

* To describe the recruited population and potentially associated factors (age, sex, etc.). * To assess the psychological pain of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst. * To assess the self-esteem of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU

Clermont-Ferrand, 63000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any adult patient consulting at the psychiatrist's office during the recruitment period (regardless of the reason for consultation) and who has provided consent to participate in this study.

Exclusion criteria

  • Minor patient or refusal to participate in the study.
  • Patient who has already completed the self-questionnaires previously (e.g., second consultation within the same week).
  • Patient unable to understand or complete the self-questionnaires (due to cognitive impairment or insufficient understanding of the French language).

Treatment and study plan

Primary outcomes

  1. score at scale a risk suicidal of Ducher (aRSD)

    Time frame: Day 1

    aRSD scale score from 0 to 10 (worse is 10)

Secondary outcomes

  1. SEST

    Time frame: Day 1

    Self-Esteem Scale (SES) score. From 0 to 24. 24 is the worste outcome

  2. VAST

    Time frame: Day 1

    Visual Analog Scale (VAS) score for psychological pain. from 0 to 10. 10 is the worse outcome.

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: RSCP

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 4, 2026
Registry last updated
Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.